GSA Capital Partners LLP Makes New $871,000 Investment in Scholar Rock Holding Corporation $SRRK

GSA Capital Partners LLP purchased a new stake in shares of Scholar Rock Holding Corporation (NASDAQ:SRRK) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 15,838 shares of the company’s stock, valued at approximately $871,000.

Several other institutional investors and hedge funds also recently made changes to their positions in SRRK. IFP Advisors Inc lifted its position in Scholar Rock by 294.1% in the 4th quarter. IFP Advisors Inc now owns 603 shares of the company’s stock valued at $27,000 after acquiring an additional 450 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in shares of Scholar Rock in the 4th quarter worth $30,000. Summit Securities Group LLC purchased a new position in shares of Scholar Rock in the fourth quarter worth $31,000. EverSource Wealth Advisors LLC raised its stake in shares of Scholar Rock by 151.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 872 shares of the company’s stock worth $38,000 after purchasing an additional 525 shares during the last quarter. Finally, Hilton Head Capital Partners LLC bought a new position in shares of Scholar Rock during the fourth quarter valued at $44,000. Institutional investors own 91.08% of the company’s stock.

Scholar Rock Price Performance

NASDAQ SRRK opened at $54.72 on Wednesday. Scholar Rock Holding Corporation has a 12 month low of $27.07 and a 12 month high of $58.49. The stock has a market cap of $6.66 billion, a price-to-earnings ratio of -15.86 and a beta of 0.69. The company’s 50 day moving average is $51.15 and its two-hundred day moving average is $48.26. The company has a current ratio of 7.02, a quick ratio of 7.02 and a debt-to-equity ratio of 0.77.

Scholar Rock (NASDAQ:SRRK) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.84) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.84). During the same quarter in the prior year, the business earned ($0.98) earnings per share. As a group, research analysts anticipate that Scholar Rock Holding Corporation will post -3.24 earnings per share for the current year.

Insider Activity at Scholar Rock

In other Scholar Rock news, Director Michael Gilman sold 2,544 shares of the stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $53.87, for a total value of $137,045.28. Following the completion of the sale, the director owned 59,511 shares in the company, valued at approximately $3,205,857.57. This represents a 4.10% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Jeffrey S. Flier sold 3,053 shares of the firm’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $53.88, for a total value of $164,495.64. Following the sale, the director directly owned 27,856 shares in the company, valued at approximately $1,500,881.28. This represents a 9.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 17,149 shares of company stock worth $923,108 in the last 90 days. Company insiders own 10.30% of the company’s stock.

Wall Street Analysts Forecast Growth

SRRK has been the subject of several research analyst reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Scholar Rock in a report on Thursday, June 18th. HC Wainwright restated a “buy” rating and set a $65.00 target price on shares of Scholar Rock in a research note on Monday, August 10th. BMO Capital Markets reaffirmed an “outperform” rating and set a $76.00 price target on shares of Scholar Rock in a report on Friday, August 7th. Citigroup lifted their price target on shares of Scholar Rock from $58.00 to $60.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Scholar Rock in a report on Friday, July 17th. Four equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Scholar Rock presently has an average rating of “Buy” and a consensus target price of $57.71.

Scholar Rock Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).